Deucrictibant Reduced Hereditary Angioedema Attack Rates
A phase 3 clinical study found that a daily oral medication significantly decreased HAE attacks over 24 weeks.
Updated on Sept. 22, 2026 in Allergies
Live Poll
Do you trust that new oral medications for chronic conditions are as effective as traditional injections?
The phase 3 CHAPTER-3 trial demonstrated that daily 40 mg doses of deucrictibant extended-release tablets reduced monthly hereditary angioedema (HAE) attack rates by 83% compared to a placebo. Participants also reported improved quality of life scores throughout the study.
Why it matters
Researchers conducted this trial to evaluate the efficacy of deucrictibant as a potential long-term prophylactic therapy for patients living with hereditary angioedema. Reducing the frequency of these attacks is a primary goal in managing the chronic, debilitating condition.
In a study of 85 patients, the deucrictibant group recorded an attack rate of 0.35 per 4 weeks, compared to 2.06 per 4 weeks for the placebo group. Nearly half of the participants receiving the treatment remained attack-free during the 24-week period.
The players
FDA
The Food and Drug Administration is the federal agency responsible for regulating pharmaceuticals and approving new drug applications for public use.
The details
The double-blind study included patients aged 12 years or older who received either the daily medication or a placebo. While 76.4% of the treatment group experienced treatment-emergent adverse events, only 56.7% of the placebo group reported such effects.
Timeline
The clinical study treatment period lasted for 24 weeks.
The application for long-term prophylaxis is planned for the first half of 2027.
The FDA target date for the on-demand treatment application is April 23, 2027.
The Big Picture
This development aligns with the regulatory benchmarks set by the FDA Prescription Drug User Fee Act, which governs the review timelines for new therapeutic applications. The study results mark a significant milestone in the ongoing efforts to expand prophylactic treatment options for chronic hereditary conditions.
For individuals with hereditary angioedema, this potential new daily oral therapy could provide a more convenient and effective way to manage attack frequency compared to current standards. Patients should monitor clinical updates as the drug moves toward its projected 2027 regulatory review dates.
The takeaway
The study suggests that daily oral prophylaxis can substantially lower attack rates and improve patient quality of life. Future regulatory filings will determine when or if this specific treatment option becomes available to the broader patient population.
Further reading
Learn more about the latest research and management strategies for Allergies.
Source note: This article includes information reported by Healio.
Live Poll
Do you trust that new oral medications for chronic conditions are as effective as traditional injections?
